Neuromodulation in Patients With Neuropathic Pain and Depression.

Inclusion Criteria: * Central or peripheral neuropathic pain * Chronic pain (present for more than 6 months) with intensity greater than or equal to 4/10 on the numerical scale * Pain present on a daily or near-daily basis (at least 4 days a week) * Patient not completely relieved by recommended drug treatments for first- and second-line neuropathic pain * Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month, and will not need to be modified for the duration of the study. * Patient with a depressive episode characterized according to DSM V criteria * Indication for motor cortex rTMS by a neurologist * Patient can be followed for the entire duration of the study * Patient having received informed consent to participate in the study, and having co-signed a consent form with the investigator * Member or beneficiary of a social security scheme Exclusion Criteria: * Industrial accident or litigation * Contraindication to rTMS or MRI (seismotherapy treatment since the previous month; epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia) * Drug or psychoactive substance abuse * Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemic disease disease) * Presence of other pain more severe than that justifying inclusion * Patient unable to understand informed consent * Patient unwilling or unable to stop treatments prohibited during the study * Patient participating in another research protocol involving a drug within the 30 days prior to inclusion * Patient deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice safeguard, family safeguard) * Minor patient